A novel, humanized anti-NKG2A therapeutic mAb shows a potential clinical role in humanized mouse models for the treatment of hematological malignancies.

**in vitro**

- NK cell
- Neoplastic or normal hematopoietic cells
- HLA-E
- NKG2A

Humanized anti-human NKG2A mAb

Killing of tumor cells

**in vivo**

- Human primary leukemias or EBV cell lines
- NKG2A+ NK cells pretreated with anti-human NKG2A mAb
- NOD SCID mouse

Rescue from disease progression

- Human primary leukemias or EBV cell lines
- CD34+ cells differentiate to NKG2A+ NK cells
- Anti-human NKG2A mAb

NSG mouse

Rescue from disease progression

Ruggeri et al., Haematologica, 2016